Compare Nike Inc (NKE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nike Inc trades at $41.28 (market cap $61.30B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× Nike Inc's market cap, and Nike Inc pays a 3.97% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NKE | VRTX | |
|---|---|---|
Market Cap | $61.30B | $134.25B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $79.17 | $529.65 |
52-Week Low | $40.75 | $376.62 |
Enterprise Value | $63.30B | $128.37B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $41.32, down 0.91% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong profitability with a 42.91% gross margin and 22.14% ROE, but revenue declined to $46.31B in 2025. Recent quarters have consistently beaten EPS estimates, with Q1 2026 EPS of $0.72 significantly exceeding expectations. Analysts maintain a consensus Buy rating with a $50.45 price target, indicating potential upside from current levels.
The outlook balances solid brand strength and earnings beats against revenue headwinds and competitive pressures. Investment opportunity lies in valuation discount to analyst targets and operational discipline, but risks include sluggish demand in key markets like China and margin compression from promotional activity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
